Opinion|Videos|July 1, 2024
Post-Relapse Treatment of a 50-Year-Old Male Patient with Vitiligo
Author(s)Anthony Nuara, MD, PhD
Continuing the discussion of a 50-year-old male patient with vitiligo, Anthony Nuara, MD, PhD, addresses the intricacies of treating patients who have relapsed or experienced a loss of efficacy following their initial treatment and highlights how to select 2nd line treatments with greater efficacy.
Advertisement
Episodes in this series
Advertisement
Related to this article
The FDA clearance allows Edesa to expand an ongoing placebo-controlled study of the CXCL10 antibody EB06 to US sites, with topline data expected in the fourth quarter of 2027.
Dermatology clinicians at a Case-Based Roundtable in Austin, Texas, discussed real-world strategies for sequencing topical therapy, phototherapy, and ruxolitinib cream across pediatric and adult vitiligo cases.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
Bitopertin Meets All End Points in Phase 3 APOLLO Trial for EPP
3
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
4
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
5